The Allogeneic cell therapy platform integrates patented and licensed technologies.
- Induced Allogeneic cell tolerance (iACT) is achieved by cloaking genes and mitigating initiation of adaptive immunity by antigen presenting cells, blocking cytotoxic activity and modulating inflammatory and phagocytotic monocytes and macrophages.
- Targeted gene editing is used to edit cell division essential locus (CDEL).
- Knocking out an invariant chain leads to loss of expression of all MHC Class I genes reliably with little effect on iPSC and differentiated cell function.
- CTIIA mutations leads to loss of HC class II expression
iPSC derived CTIIA null differentiated cells should not be able to present antigen even if the differentiated population contains AP capable cells.
Allogeneic cells not recognized by immune system.
Allogeneic Cell Therapy Platform Technologies